Feb 05, 2024
BackgroundTransthyretin cardiac amyloidosis (ATTR‐CA) is a progressive and ultimately fatal cardiomyopathy. Biomarkers reflecting multiorgan dysfunction are of…
Jan 02, 2024
BackgroundTafamidisexternal link, opens in a new tab was approved to treat patients with transthyretinexternal link, opens in a new tab amyloid…
Dec 14, 2023
Disease OverviewImmunoglobulin light chain amyloidosis is a clonal, nonproliferative plasma cell disorder in which fragments of immunoglobulin light or heavy chain…
Nov 30, 2023
Abstract:Transthyretincardiac amyloidosis is a rare disease that has gained significant attention in recent years because of misfolding of transthyretin fibrils…
Nov 23, 2023
Key PointsQuestion  Does tafamidis, 80 mg, affect cardiac function in patients with transthyretin amyloid cardiomyopathy?Findings  In this post hoc…
Oct 05, 2023
Amyloidoses represent a group of diseases characterized by the pathological accumulation in the extracellular area of insoluble misfolded protein material called “…
Jan 28, 2023
This study reports health-related quality of life (HRQL) among newly-diagnosed immunoglobulin light-chain (AL) patients (n = 914) treated with a bortezomib-based…
Jan 22, 2023
The American College of Cardiology (ACC) has a long history of developing documents (eg, decision pathways, health policy statements, appropriate use criteria) to…
Jan 19, 2023
Background: Transthyretin amyloid cardiomyopathy (ATTR-CM) is a morbid condition, though recent advances in diagnosis and therapy stand to change its natural…
Dec 06, 2022
Amyloidosis is a collection of diseases caused by the misfolding of proteins that aggregate into insoluble amyloid fibrils and deposit in tissues. While these…